Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods relate to in vivo and ex vivo enrichment of HIV-specific CD4 T cells. In certain embodiments, the disclosed compositions and methods can incorporate therapy in order to further enhance the HIV-specific CD4 T cells.
Type:
Grant
Filed:
July 8, 2016
Date of Patent:
May 14, 2024
Assignee:
American Gene Technologies International Inc.
Abstract: The invention relates to recombinant measles virus expressing Lassa virus polypeptides, and concerns in particular immunogenic LASV particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of a Lassa virus. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Lassa virus.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
May 7, 2024
Assignees:
INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Abstract: A strong insulator fragment from foamy virus, which can be used to insulate expression of a transgene and reduce genotoxicity of integrating vectors comprising such. The insulator fragment can also be used in gene targeting constructs in gene editing.
Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
Type:
Grant
Filed:
March 8, 2021
Date of Patent:
April 23, 2024
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth College
Inventors:
Barney Graham, Jason Mclellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
Abstract: The present disclosure provides AAV variants that exhibit a preference for retrograde movement in neurons and methods of using such variants.
Type:
Grant
Filed:
March 23, 2021
Date of Patent:
March 26, 2024
Assignee:
Howard Hughes Medical Institute
Inventors:
Joshua Dudman, Adam Hantman, Bum-Yeol Hwang, Alla Karpova, Loren Looger, Kimberly Ritola, David Schaffer, Dougal Gowanlock Robinson Tervo, Sarada Viswanathan
Abstract: A hydrogel material for use in a human subject or other mammal includes a collection of microgel particles having one or more network cross linker components, wherein the microgel particles, when exposed to an endogenous or exogenous annealing agent, links the microgel particles together in situ to form a covalently-stabilized scaffold of microgel particles having pores formed between the microgel particles wherein the pores are substantially devoid of hydrogel.
Type:
Grant
Filed:
July 30, 2022
Date of Patent:
March 19, 2024
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Dino Di Carlo, Westbrook Weaver, Tatiana Segura, Jaekyung Koh, Philip Scumpia, Donald R. Griffin
Abstract: A hydrogel material for modulating an immune response in a human subject or other mammal includes a collection of microgel particles having one or more network cross linker components, wherein the microgel particles, when exposed to an endogenous or exogenous annealing agent, links the microgel particles together in situ to form a covalently-stabilized scaffold of microgel particles having interstitial spaces formed between the microgel particles and wherein the collection of microgel particles further includes at least one of an antigen and an adjuvant.
Type:
Grant
Filed:
February 14, 2017
Date of Patent:
March 19, 2024
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Dino Di Carlo, Westbrook Weaver, Tatiana Segura, Philip Scumpia, Donald R. Griffin
Abstract: The present invention relates to a cell comprising (aa) a nucleic acid comprising in 5? to 3? direction (i) at least one adeno-associated virus (AAV) inverted terminal repeat (ITR) sequence; (ii) a promoter which is capable of being activated by (a) helper polypeptide(s) and optionally (a) helper polynucleotide(s); and (iii) a transgenic coding sequence under the control of said promoter of (aa)(ii); and (ab) a nucleic acid comprising in 5? to 3? direction (i) a promoter which is capable of being activated by said helper polypeptide(s) and optionally said helper polynucleotide(s); and (ii) at least one AAV rep gene coding sequence under the control of said promoter of (ab)(i); wherein said cell does not comprise an AAV cap gene and/or is not able to express any AAV cap gene product.
Type:
Grant
Filed:
September 22, 2021
Date of Patent:
March 12, 2024
Inventors:
Ulrich Koszinowski, Simona Langer, Zsolt Ruzsics, Christian Thirion
Abstract: The present invention includes compositions and methods for T cell genome editing and screening in vivo. In certain aspects, the invention includes an sgRNA library for genome-scale mutagenesis.
Abstract: Provided herein are methods of performing viral filtration on a fluid including a recombinant antibody, and the use of these methods in methods of manufacturing or producing the recombinant antibody.
Type:
Grant
Filed:
April 20, 2022
Date of Patent:
March 5, 2024
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Bianca Olson, Saravanamoorthy Rajendran, Ryan Tedstone
Abstract: The present invention relates to compositions and methods involving diagnostic tests with multiple test antigens. The present invention involves the expanded use of test antigens as cross-reactive control antigens (CCAs). The invention advantageously provides for enhanced test results analysis by simultaneously providing both test antigen and CCA signal results. These results, in turn, allow useful sample comparison and cross-reference between samples to more accurately identify and verify the fidelity of test results obtained for multiple infective agents at once. The present invention may include compositions and methods for detecting infection by Zika virus or another flavivirus, and may distinguish between infections caused by genetically similar agents.
Type:
Grant
Filed:
February 11, 2021
Date of Patent:
February 27, 2024
Assignee:
InBios International, Inc.
Inventors:
James William Needham, Syamal Raychaudhuri
Abstract: The present invention pertains to the field of industrial scale inactivation of various enteroviruses and large and industrial scale production of enterovirus vaccine compositions and combinations of various enteroviruses so obtained.
Abstract: Provided herein are compositions and methods for packaging a recombinant adeno-associated vims (rAAV) particle comprising using inverted terminal repeats (ITRs) and rep genes of different serotypes and/or using chimeric rep genes.
Type:
Grant
Filed:
March 6, 2019
Date of Patent:
February 20, 2024
Assignee:
University of Florida Research Foundation, Incorporated
Inventors:
Mavis Agbandje-McKenna, Mario Mietzsch, Robert McKenna
Abstract: The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.
Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Type:
Grant
Filed:
January 10, 2022
Date of Patent:
February 13, 2024
Assignee:
Novavax, Inc.
Inventors:
Gale Smith, Michael J. Massare, Jing-Hui Tian
Abstract: Compared to an unadjuvanted vaccine, an adjuvanted influenza vaccine can reduce by almost a quarter the risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) in elderly recipients. Thus the invention provides a method for immunizing an elderly subject by administering an adjuvanted influenza vaccine, whereby the subject's risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) is reduced relative to an elderly subject who receives an unadjuvanted influenza vaccine.
Abstract: Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
Type:
Grant
Filed:
April 15, 2022
Date of Patent:
January 30, 2024
Assignee:
Abacus Bioscience, Inc.
Inventors:
Edward A. Clark, Deborah L. Fuller, Che-Leung Law, Amanda Mak
Abstract: Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.
Type:
Grant
Filed:
October 30, 2018
Date of Patent:
January 16, 2024
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Taco Gilles Uil, Soumitra Roy, Selina Khan, Jerôme H. H. V. Custers
Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using an inhibitor of UFM1 activity or expression and/or an inhibitor of UFL1 activity or expression to reduce a cancer cell's ability to carry out a DDR, thereby increasing the sensitivity of cancer cells to treatment with a DNA damaging therapy such as radiation or chemotherapy, are provided.
Type:
Grant
Filed:
January 11, 2018
Date of Patent:
January 9, 2024
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Evanthia Galanis, S. Keith Anderson, Cheyne B. Kurokawa, Ianko D. Iankov